Surface Matters: How to Incorporate Conjugates in Lipid Nanoparticles Fighting Glioblastoma DOI
Maria Mendes, José Sereno, M. Luísa Ramos

et al.

Published: Jan. 1, 2025

Language: Английский

Engineering Multifunctional Peptide-Decorated Nanofibers for Targeted Delivery of Temozolomide across the Blood–Brain Barrier DOI Creative Commons
Rosa Bellavita, Teresa Barra, Simone Braccia

et al.

Molecular Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown

Published: March 16, 2025

A nanoplatform based on self-assembling peptides was developed with the ability to effectively transport and deliver a wide range of moieties across blood–brain barrier (BBB) for treatment glioblastoma. Its surface functionalized have targeted release TMZ thanks targeting peptide that binds EGFRvIII, which is overexpressed tumor cells, gH625, acts as an enhancer penetration. Furthermore, on-demand achieved through matrix metalloproteinase-9 (MMP-9) cleavage. Nanofibers were characterized their stability, critical aggregation concentration, morphology. Next, effect both 2D 3D glioblastoma/astrocytoma (U-87) glioma (U-118) cell lines evaluated. The Annexin V/Propidium iodide showed increase in necrotic apoptotic morphological analysis allowed discover U-118 U-87 spheroids are smaller surface, perimeter, Feret's diameter when treated NF-TMZ. nanofiber demonstrated permeate BBB vitro spheroidal biodynamic model. Finally, there no cytotoxic effects nanofibers without drug spheroids, while significant decrease viability observed NF-TMZ used. Overall, these results open new opportunities evaluation efficacy safety this vivo studies.

Language: Английский

Citations

0
Anticancer potential of lactoferrin: effects, drug synergy and molecular interactions DOI

Dyada Blanca León-Flores,

Ignacio Siañez-Estrada, Blanca Flor Iglesias-Figueroa

et al.

BioMetals, Journal Year: 2025, Volume and Issue: unknown

Published: March 21, 2025

Language: Английский

Citations

0
Nanoparticle‐Based Therapeutics for Glioblastoma Multiforme Treatment DOI
Papihra Sethi, Shampa Ghosh, Krishna Kumar Singh

et al.

Advanced Therapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: April 8, 2025

Abstract Glioblastoma multiforme (GBM) is a grade 4 primary malignant brain neoplasm with poor prognosis. GBM has an average survival of 12–18 months despite aggressive treatments, such as maximal safe resection, radiation, and chemotherapy temozolomide. always associated high incidences treatment resistance recurrence, which largely driven by glioma stem cells presents significant therapeutic challenges. The blood–brain barrier (BBB) the most obstacle in treating since it restricts delivery agents to tumor site. Recent advancements nanotechnology offer promising alternatives overcome restrictions, enabling targeted drug significantly reducing systemic toxicity. Additionally, discussing various types nanoparticles liposomes, lipid‐based, dendrimers, polymeric, metallic that have shown promise preclinical models for become pertinent. These can attach glioblastoma using antigens membrane receptors site‐directed targeting. Furthermore, potential cross BBB, enhancing minimizing off‐target effects. This review explores latest nanoparticle‐based therapies their revolutionize treatment, particularly through precise targeting controlled release within microenvironment.

Language: Английский

Citations

0
Enhanced Glioblastoma Treatment via Carbon-coated Perovskite Nanohybrid: Synergistic Effects of Targeted Chemotherapy and Magnetic Hyperthermia DOI
Ayça Tunçel, Buse Sert, Derya Özel

et al.

Journal of Drug Delivery Science and Technology, Journal Year: 2025, Volume and Issue: unknown, P. 106976 - 106976

Published: April 1, 2025

Language: Английский

Citations

0
Surface Matters: How to Incorporate Conjugates in Lipid Nanoparticles Fighting Glioblastoma DOI
Maria Mendes, José Sereno, M. Luísa Ramos

et al.

Published: Jan. 1, 2025

Language: Английский

Citations

0